{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:58:47Z","timestamp":1791863927810,"version":"4.3.4"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40261-021-01038-1","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T06:44:18Z","timestamp":1619073858000},"page":"513-527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Riboflavin in Neurological Diseases: A Narrative Review"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6666-7244","authenticated-orcid":false,"given":"Domenico","family":"Plantone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"1038_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673\u201383. https:\/\/doi.org\/10.1038\/nrd1468.","journal-title":"Nat Rev Drug Discov."},{"key":"1038_CR2","doi-asserted-by":"publisher","first-page":"e0117705","DOI":"10.1371\/journal.pone.0117705","volume":"10","author":"HM Vesterinen","year":"2015","unstructured":"Vesterinen HM, Connick P, Irvine CMJ, Sena ES, Egan KJ, Carmichael GG, et al. Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis. PLoS ONE. 2015;10:e0117705. https:\/\/doi.org\/10.1371\/journal.pone.0117705.","journal-title":"PLoS ONE"},{"key":"1038_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/77.6.1352","author":"HJ Powers","year":"2003","unstructured":"Powers HJ. Riboflavin (vitamin B-2) and health. Am J Clin Nutr. 2003. https:\/\/doi.org\/10.1093\/ajcn\/77.6.1352.","journal-title":"Am J Clin Nutr."},{"key":"1038_CR4","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/ijms21030950","volume":"21","author":"N Suwannasom","year":"2020","unstructured":"Suwannasom N, Kao I, Pru\u00df A, Georgieva R, B\u00e4umler H. Riboflavin: The health benefits of a forgotten natural vitamin. Int J Mol Sci. 2020;21:950. https:\/\/doi.org\/10.3390\/ijms21030950.","journal-title":"Int J Mol Sci."},{"key":"1038_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1017\/S0007114510001005","volume":"104","author":"K Murakami","year":"2010","unstructured":"Murakami K, Miyake Y, Sasaki S, Tanaka K, Fukushima W, Kiyohara C, et al. Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson\u2019s disease: a case-control study in Japan. Br J Nutr. 2010;104:757\u201364. https:\/\/doi.org\/10.1017\/S0007114510001005.","journal-title":"Br J Nutr"},{"key":"1038_CR6","doi-asserted-by":"publisher","first-page":"958","DOI":"10.22038\/IJBMS.2017.9257","volume":"20","author":"M Naghashpour","year":"2017","unstructured":"Naghashpour M, Jafarirad S, Amani R, Sarkaki A, Saedisomeolia A. Update on riboflavin and multiple sclerosis: a systematic review. Iran J Basic Med Sci. 2017;20:958\u201366. https:\/\/doi.org\/10.22038\/IJBMS.2017.9257.","journal-title":"Iran J Basic Med Sci."},{"key":"1038_CR7","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/jcpt.12548","volume":"42","author":"DF Thompson","year":"2017","unstructured":"Thompson DF, Saluja HS. Prophylaxis of migraine headaches with riboflavin: a systematic review. J Clin Pharm Ther. 2017;42:394\u2013403. https:\/\/doi.org\/10.1111\/jcpt.12548.","journal-title":"J. Clin Pharm Ther."},{"key":"1038_CR8","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000343111","volume":"61","author":"CA Northrop-Clewes","year":"2012","unstructured":"Northrop-Clewes CA, Thurnham DI. The discovery and characterization of riboflavin. Ann Nutr Metab. 2012;61:224\u201330. https:\/\/doi.org\/10.1159\/000343111.","journal-title":"Ann Nutr Metab."},{"key":"1038_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1024\/0300-9831\/a000170","volume":"83","author":"M Naghashpour","year":"2013","unstructured":"Naghashpour M, Majdinasab N, Shakerinejad G, Kouchak M, Haghighizadeh MH, Jarvandi F, et al. Riboflavin supplementation to patients with multiple sclerosis does not improve disability status nor is riboflavin supplementation correlated to homocysteine. Int J Vitam Nutr Res. 2013;83:281\u201390. https:\/\/doi.org\/10.1024\/0300-9831\/a000170.","journal-title":"Int J Vitam Nutr Res."},{"key":"1038_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1753-4887.1972.tb03991.x","volume":"30","author":"DB McCormick","year":"1972","unstructured":"McCormick DB. The fate of riboflavin in the mammal. Nutr Rev. 1972;30:75\u20139. https:\/\/doi.org\/10.1111\/j.1753-4887.1972.tb03991.x.","journal-title":"Nutr Rev."},{"key":"1038_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/jps.2600560112","volume":"56","author":"WJ Jusko","year":"1967","unstructured":"Jusko WJ, Levy G. Absorption, metabolism, and excretion of riboflavin-5\u2032-phosphate in man. J Pharm Sci. 1967;56:58\u201362. https:\/\/doi.org\/10.1002\/jps.2600560112.","journal-title":"J Pharm Sci."},{"key":"1038_CR12","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.3390\/ijms21113847","volume":"21","author":"S Mosegaard","year":"2020","unstructured":"Mosegaard S, Dipace G, Bross P, Carlsen J, Gregersen N, Olsen RKJ. Riboflavin deficiency\u2014implications for general human health and inborn errors of metabolism. Int J Mol Sci. 2020;21:3847. https:\/\/doi.org\/10.3390\/ijms21113847.","journal-title":"Int J Mol Sci."},{"key":"1038_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5925\/jnsv1954.1.2_6","volume":"1","author":"S Iinuma","year":"1955","unstructured":"Iinuma S. Synthesis of riboflavin by intestinal bacteria. J Vitaminol (Kyoto). 1955;1:6\u201313. https:\/\/doi.org\/10.5925\/jnsv1954.1.2_6.","journal-title":"J Vitaminol (Kyoto)."},{"key":"1038_CR14","doi-asserted-by":"publisher","first-page":"G601","DOI":"10.1152\/ajpgi.00231.2013","volume":"305","author":"HM Said","year":"2013","unstructured":"Said HM. Recent advances in transport of water-soluble vitamins in organs of the digestive system: A focus on the colon and the pancreas. Am J Physiol Gastrointest Liver Physiol. 2013;305:G601\u201310. https:\/\/doi.org\/10.1152\/ajpgi.00231.2013.","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"1038_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0006-2944(85)90106-1","volume":"34","author":"WSA Innis","year":"1985","unstructured":"Innis WSA, McCormick DB, Merrill AH. Variations in riboflavin binding by human plasma: identification of immunoglobulins as the major proteins responsible. Biochem Med. 1985;34:151\u201365. https:\/\/doi.org\/10.1016\/0006-2944(85)90106-1.","journal-title":"Biochem Med."},{"key":"1038_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cbi.2006.04.014","volume":"163","author":"F Depeint","year":"2006","unstructured":"Depeint F, Bruce WR, Shangari N, Mehta R, O\u2019Brien PJ. Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism. Chem Biol Interact. 2006;163:94\u2013112. https:\/\/doi.org\/10.1016\/j.cbi.2006.04.014.","journal-title":"Chem Biol Interact."},{"key":"1038_CR17","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.2174\/092986710793205462","volume":"17","author":"JB Henriques","year":"2010","unstructured":"Henriques JB, Olsen KR, Bross P, Gomes MC. Emerging roles for riboflavin in functional rescue of mitochondrial \u03b2-OXIDATION FLAVOENZYMES. Curr Med Chem. 2010;17:3842\u201354. https:\/\/doi.org\/10.2174\/092986710793205462.","journal-title":"Curr Med Chem."},{"key":"1038_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3181\/00379727-181-42247","volume":"181","author":"WSA Innis","year":"1986","unstructured":"Innis WSA, McCormick DB, Merrill AH, Murray DR, Nixon DW. Immunoglobulins associated with elevated riboflavin binding by plasma from cancer patients. Proc Soc Exp Biol Med. 1986;181:237\u201341. https:\/\/doi.org\/10.3181\/00379727-181-42247.","journal-title":"Proc Soc Exp Biol Med."},{"key":"1038_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/ajcn\/46.5.830","volume":"46","author":"JL Chastain","year":"1987","unstructured":"Chastain JL, McCormick DB. Flavin catabolites\u202f: Identification and quantitation in human urine. Am J Clin Nutr. 1987;46:830\u20134. https:\/\/doi.org\/10.1093\/ajcn\/46.5.830.","journal-title":"Am J Clin Nutr."},{"issue":"7","key":"1038_CR20","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3945\/an.116.012716","volume":"15","author":"JT Pinto","year":"2016","unstructured":"Pinto JT, Zempleni J. Riboflavin. Adv Nutr. 2016;15(7):973\u20135. https:\/\/doi.org\/10.3945\/an.116.012716.","journal-title":"Adv Nutr."},{"key":"1038_CR21","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.2307\/4583104","volume":"54","author":"WH Sebrell","year":"1939","unstructured":"Sebrell WH, Butler RE. Riboflavin deficiency in man (Ariboflavinosis). US Public Health Rept. 1939;54:2121\u201331.","journal-title":"US Public Health Rept."},{"key":"1038_CR22","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2105\/ajph.31.4.344","volume":"31","author":"VP Sydenstricker","year":"1941","unstructured":"Sydenstricker VP. Clinical Manifestations of Ariboflavinosis. Am J Public Health Nations Health. 1941;31:344\u201350. https:\/\/doi.org\/10.2105\/ajph.31.4.344.","journal-title":"Am J Public Health Nations Health."},{"issue":"8","key":"1038_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/nu8020068","volume":"27","author":"DO Kennedy","year":"2016","unstructured":"Kennedy DO. B vitamins and the brain: Mechanisms, dose and efficacy\u2014A review. Nutrients. 2016;27(8):68. https:\/\/doi.org\/10.3390\/nu8020068.","journal-title":"Nutrients"},{"key":"1038_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3389\/fneur.2017.00333","volume":"8","author":"ET Marashly","year":"2017","unstructured":"Marashly ET, Bohlega SA. Riboflavin has neuroprotective potential: Focus on Parkinson\u2019s disease and migraine. Front Neurol. 2017;8:333. https:\/\/doi.org\/10.3389\/fneur.2017.00333.","journal-title":"Front Neurol."},{"key":"1038_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1249\/MSS.0b013e31890eb86","volume":"41","author":"NR Rodriguez","year":"2009","unstructured":"Rodriguez NR, Di Marco NM, Langley S, American Dietetic Association, Dietitians of Canada, American College of Sports Medicine. American College of Sports Medicine position stand. Nutrition and athletic performance. Med Sci Sports Exerc. 2009;41:709\u201331. https:\/\/doi.org\/10.1249\/MSS.0b013e31890eb86.","journal-title":"Med Sci Sports Exerc."},{"key":"1038_CR26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1079\/bjn19930054","volume":"69","author":"MJ Soares","year":"1993","unstructured":"Soares MJ, Satyanarayana K, Bamjlt MS, Jacob CM, Venkata Ramana Y, Sudhakar RS. The effect of exercise on the riboflavin status of adult men. Br J Nutr. 1993;69:541\u201351. https:\/\/doi.org\/10.1079\/bjn19930054.","journal-title":"Br J Nutr."},{"key":"1038_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1159\/000095828","volume":"50","author":"D Majchrzak","year":"2006","unstructured":"Majchrzak D, Singer I, M\u00e4nner M, Rust P, Genser D, Wagner KH, et al. B-vitamin status and concentrations of homocysteine in Austrian omnivores, vegetarians and vegans. Ann Nutr Metab. 2006;50:485\u201391. https:\/\/doi.org\/10.1159\/000095828.","journal-title":"Ann Nutr Metab."},{"key":"1038_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/ajcn\/76.1.100","volume":"76","author":"CL Larsson","year":"2002","unstructured":"Larsson CL, Johansson GK. Dietary intake and nutritional status of young vegans and omnivores in Sweden. Am J Clin Nutr. 2002;76:100\u20136. https:\/\/doi.org\/10.1093\/ajcn\/76.1.100.","journal-title":"Am J Clin Nutr."},{"key":"1038_CR29","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/sj.ejcn.1601629","volume":"57","author":"A Waldmann","year":"2003","unstructured":"Waldmann A, Koschizke JW, Leitzmann C, Hahn A. Dietary intakes and lifestyle factors of a vegan population in Germany: results from the German vegan study. Eur J Clin Nutr. 2003;57:947\u201355. https:\/\/doi.org\/10.1038\/sj.ejcn.1601629.","journal-title":"Eur J Clin Nutr."},{"key":"1038_CR30","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/jn\/123.5.915","volume":"123","author":"WA Boisvert","year":"1993","unstructured":"Boisvert WA, Mendoza I, Castaneda C, De Portocarrero L, Solomons NW, Gershoff SN, et al. Riboflavin requirement of healthy elderly humans and its relationship to macronutrient composition of the diet. J Nutr. 1993;123:915\u201325. https:\/\/doi.org\/10.1093\/jn\/123.5.915.","journal-title":"J Nutr."},{"key":"1038_CR31","first-page":"321","volume":"67","author":"H B\u00f6hles","year":"1997","unstructured":"B\u00f6hles H. Antioxidative vitamins in prematurely and maturely born infants. Int J Vitam Nutr Res. 1997;67:321\u20138.","journal-title":"Int J Vitam Nutr Res."},{"key":"1038_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00404-006-0304-2","volume":"276","author":"O Paamoni-Keren","year":"2007","unstructured":"Paamoni-Keren O, Silberstein T, Burg A, Raz I, Mazor M, Saphier O. Oxidative stress as determined by glutathione (GSH) concentrations in venous cord blood in elective cesarean delivery versus uncomplicated vaginal delivery. Arch Gynecol Obstet. 2007;276:43\u20136. https:\/\/doi.org\/10.1007\/s00404-006-0304-2.","journal-title":"Arch Gynecol Obstet."},{"key":"1038_CR33","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1017\/S0007114512005351","volume":"110","author":"AI Mazur-Bialy","year":"2013","unstructured":"Mazur-Bialy AI, Buchala B, Plytycz B. Riboflavin deprivation inhibits macrophage viability and activity-a study on the RAW 264.7 cell line. Br J Nutr. 2013;110:509\u201314. https:\/\/doi.org\/10.1017\/S0007114512005351.","journal-title":"Br J Nutr."},{"key":"1038_CR34","first-page":"793","volume":"66","author":"AI Mazur-Bialy","year":"2015","unstructured":"Mazur-Bialy AI, Pochec E, Plytycz B. Immunomodulatory effect of riboflavin deficiency and enrichment\u2014reversible pathological response versus silencing of inflammatory activation. J Physiol Pharmacol. 2015;66:793\u2013802.","journal-title":"J Physiol Pharmacol."},{"key":"1038_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ejphar.2004.04.004","volume":"492","author":"T Toyosawa","year":"2004","unstructured":"Toyosawa T, Suzuki M, Kodama K, Araki S. Effects of intravenous infusion of highly purified vitamin B2 on lipopolysaccharide-induced shock and bacterial infection in mice. Eur J Pharmacol. 2004;492:273\u201380. https:\/\/doi.org\/10.1016\/j.ejphar.2004.04.004.","journal-title":"Eur J Pharmacol."},{"key":"1038_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ejphar.2004.04.019","volume":"493","author":"T Toyosawa","year":"2004","unstructured":"Toyosawa T, Suzuki M, Kodama K, Araki S. Potentiation by amino acid of the therapeutic effect of highly purified vitamin B2 in mice with lipopolysaccharide-induced shock. Eur J Pharmacol. 2004;493:177\u201382. https:\/\/doi.org\/10.1016\/j.ejphar.2004.04.019.","journal-title":"Eur J Pharmacol."},{"key":"1038_CR37","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1017\/S0007114514000178","volume":"111","author":"M Ashoori","year":"2014","unstructured":"Ashoori M, Saedisomeolia A. Riboflavin (vitamin B2) and oxidative stress: a review. Br J Nutr. 2014;111:1985\u201391. https:\/\/doi.org\/10.1017\/S0007114514000178.","journal-title":"Br J Nutr."},{"key":"1038_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1476-511X-10-177","volume":"10","author":"AA Qureshi","year":"2011","unstructured":"Qureshi AA, Tan X, Reis JC, Badr MZ, Papasian CJ, Morrison DC, et al. Suppression of nitric oxide induction and pro-inflammatory cytokines by novel proteasome inhibitors in various experimental models. Lipids Health Dis. 2011;10:177. https:\/\/doi.org\/10.1186\/1476-511X-10-177.","journal-title":"Lipids Health Dis."},{"key":"1038_CR39","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/s0092-8674(94)90482-0","volume":"78","author":"VJ Palombella","year":"1994","unstructured":"Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitinproteasome pathway is required for processing the NF-\u03baB1 precursor protein and the activation of NF-\u03baB. Cell. 1994;78:773\u201385. https:\/\/doi.org\/10.1016\/s0092-8674(94)90482-0.","journal-title":"Cell"},{"key":"1038_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12950-016-0145-0","volume":"13","author":"S Dey","year":"2016","unstructured":"Dey S, Bishayi B. Riboflavin along with antibiotics balances reactive oxygen species and inflammatory cytokines and controls Staphylococcus aureus infection by boosting murine macrophage function and regulates inflammation. J Inflamm (Lond). 2016;13:36. https:\/\/doi.org\/10.1186\/s12950-016-0145-0.","journal-title":"J Inflamm (Lond)."},{"key":"1038_CR41","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1111\/ene.14120","volume":"27","author":"C Mattiuzzi","year":"2020","unstructured":"Mattiuzzi C, Lippi G. Updates on migraine epidemiology. Eur J Neurol. 2020;27:e13. https:\/\/doi.org\/10.1111\/ene.14120.","journal-title":"Eur J Neurol."},{"key":"1038_CR42","doi-asserted-by":"publisher","first-page":"g1416","DOI":"10.1136\/bmj.g1416","volume":"348","author":"TJ Schwedt","year":"2014","unstructured":"Schwedt TJ. Chronic migraine. BMJ. 2014;348:g1416. https:\/\/doi.org\/10.1136\/bmj.g1416.","journal-title":"BMJ"},{"key":"1038_CR43","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S1474-4422(15)00198-2","volume":"14","author":"HC Diener","year":"2015","unstructured":"Diener HC, Charles A, Goadsby PJ, Holle D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol. 2015;14:1010\u201322. https:\/\/doi.org\/10.1016\/S1474-4422(15)00198-2.","journal-title":"Lancet Neurol."},{"key":"1038_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12916-015-0522-1","volume":"13","author":"DD Mitsikostas","year":"2015","unstructured":"Mitsikostas DD, Rapoport AM. New players in the preventive treatment of migraine. BMC Med. 2015;13:279. https:\/\/doi.org\/10.1186\/s12916-015-0522-1.","journal-title":"BMC Med."},{"key":"1038_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11916-015-0521-0","volume":"19","author":"AJ Starling","year":"2015","unstructured":"Starling AJ, Vargas BB. A narrative review of evidence-based preventive options for chronic migraine. Curr Pain Headache Rep. 2015;19:49. https:\/\/doi.org\/10.1007\/s11916-015-0521-0.","journal-title":"Curr Pain Headache Rep."},{"key":"1038_CR46","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults report of the quality standards subcommittee of the American academy of neurology and the American headache society. Neurology. 2012;78:1337\u201345. https:\/\/doi.org\/10.1212\/WNL.0b013e3182535d20.","journal-title":"Neurology"},{"key":"1038_CR47","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1212\/WNL.0b013e3182535d0c","volume":"78","author":"S Holland","year":"2012","unstructured":"Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults Report of the quality standards subcommittee of the American academy of neurology and the American headache society. Neurology. 2012;78:1346\u201353. https:\/\/doi.org\/10.1212\/WNL.0b013e3182535d0c.","journal-title":"Neurology"},{"key":"1038_CR48","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.spen.2013.09.002","volume":"20","author":"WR Yorns","year":"2013","unstructured":"Yorns WR, Hardison HH. Mitochondrial dysfunction in migraine. Semin Pediatr Neurol. 2013;20:188\u201393. https:\/\/doi.org\/10.1016\/j.spen.2013.09.002.","journal-title":"Semin Pediatr Neurol."},{"key":"1038_CR49","first-page":"877","volume":"14","author":"R Alp","year":"2010","unstructured":"Alp R, Selek \u015e, Ilhan Alp S, Ta\u015fkin A, Ko\u00e7yi\u01e7it A. Oxidative and antioxidative balance in patients of migraine. Eur Rev Med Pharmacol Sci. 2010;14:877\u201382.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"1038_CR50","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12011-008-8193-9","volume":"126","author":"D Tuncel","year":"2008","unstructured":"Tuncel D, Tolun FI, Gokce M, \u0130mrek S, Ekerbi\u00e7er H. Oxidative stress in migraine with and without aura. Biol Trace Elem Res. 2008;126:92\u20137. https:\/\/doi.org\/10.1007\/s12011-008-8193-9.","journal-title":"Biol Trace Elem Res."},{"key":"1038_CR51","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1046\/j.1468-2982.1994.1405328.x","volume":"14","author":"J Schoenen","year":"1994","unstructured":"Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia. 1994;14:328\u20139. https:\/\/doi.org\/10.1046\/j.1468-2982.1994.1405328.x.","journal-title":"Cephalalgia"},{"key":"1038_CR52","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1212\/wnl.50.2.466","volume":"50","author":"J Schoenen","year":"1998","unstructured":"Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology. 1998;50:466\u201370. https:\/\/doi.org\/10.1212\/wnl.50.2.466.","journal-title":"Neurology"},{"key":"1038_CR53","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.14661\/1344","volume":"7","author":"A Rahimdel","year":"2015","unstructured":"Rahimdel A, Zeinali A, Yazdian-Anari P, Hajizadeh R, Arefnia E. Effectiveness of vitamin B2 versus sodium valproate in migraine prophylaxis: a randomized clinical trial. Electron Phys. 2015;7:1344\u20138. https:\/\/doi.org\/10.14661\/1344.","journal-title":"Electron Phys."},{"key":"1038_CR54","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1468-1331.2004.00813.x","volume":"11","author":"C Boehnke","year":"2004","unstructured":"Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einh\u00e4upl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: An open study in a tertiary care centre. Eur J Neurol. 2004;11:475\u20137. https:\/\/doi.org\/10.1111\/j.1468-1331.2004.00813.x.","journal-title":"Eur J Neurol."},{"key":"1038_CR55","first-page":"223","volume":"16","author":"NJ Nambiar","year":"2011","unstructured":"Nambiar NJ, Aiyappa C, Srinivasa R. Oral riboflavin versus oral propranolol in migraine prophylaxis: An open label randomized controlled trial. Neurol Asia. 2011;16:223\u20139.","journal-title":"Neurol Asia."},{"key":"1038_CR56","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s10194-015-0516-6","volume":"16","author":"C Gaul","year":"2015","unstructured":"Gaul C, Diener HC, Danesch U. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain. 2015;16:516. https:\/\/doi.org\/10.1186\/s10194-015-0516-6.","journal-title":"J Headache Pain."},{"key":"1038_CR57","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1526-4610.2004.04170.x","volume":"44","author":"M Maizels","year":"2004","unstructured":"Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache. 2004;44:885\u201390. https:\/\/doi.org\/10.1111\/j.1526-4610.2004.04170.x.","journal-title":"Headache"},{"key":"1038_CR58","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1177\/0883073808318053","volume":"23","author":"SC MacLennan","year":"2008","unstructured":"MacLennan SC, Wade FM, Forrest KML, Ratanayake PD, Fagan E, Antony J. High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J Child Neurol. 2008;23:1300\u20134. https:\/\/doi.org\/10.1177\/0883073808318053.","journal-title":"J Child Neurol."},{"key":"1038_CR59","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1177\/0333102410365106","volume":"30","author":"J Bruijn","year":"2010","unstructured":"Bruijn J, Duivenvoorden H, Passchier J, Locher H, Dijkstra N, Arts WF. Medium-dose riboflavin as a prophylactic agent in children with migraine: A preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia. 2010;30:1426\u201334. https:\/\/doi.org\/10.1177\/0333102410365106.","journal-title":"Cephalalgia"},{"key":"1038_CR60","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10194-009-0142-2","volume":"10","author":"M Cond\u00f3","year":"2009","unstructured":"Cond\u00f3 M, Posar A, Arbizzani A, Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain. 2009;10:361\u20135. https:\/\/doi.org\/10.1007\/s10194-009-0142-2.","journal-title":"J. Headache Pain."},{"key":"1038_CR61","doi-asserted-by":"publisher","first-page":"132","DOI":"10.14238\/pi52.3.2012.132-7","volume":"52","author":"A Athaillah","year":"2012","unstructured":"Athaillah A, Dimyati Y, Saing JH, Saing B, Hakimi H, Lelo A. Riboflavin as migraine prophylaxis in adolescents. Paediatr Indones. 2012;52:132\u20137.","journal-title":"Paediatr Indones."},{"key":"1038_CR62","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/S0140-6736(16)30959-X","volume":"389","author":"WJ Brownlee","year":"2017","unstructured":"Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389:1336\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(16)30959-X.","journal-title":"Lancet"},{"key":"1038_CR63","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40263-018-0538-0","volume":"32","author":"F De Angelis","year":"2018","unstructured":"De Angelis F, Plantone D, Chataway J. Pharmacotherapy in secondary progressive multiple sclerosis: an overview. CNS Drugs. 2018;32:499\u2013526. https:\/\/doi.org\/10.1007\/s40263-018-0538-0.","journal-title":"CNS Drugs"},{"key":"1038_CR64","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, S\u00f8rensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278\u201386. https:\/\/doi.org\/10.1212\/WNL.0000000000000560.","journal-title":"Neurology"},{"key":"1038_CR65","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1474-4422(07)70243-0","volume":"6","author":"DH Miller","year":"2007","unstructured":"Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol. 2007;6:903\u201312. https:\/\/doi.org\/10.1016\/S1474-4422(07)70243-0.","journal-title":"Lancet Neurol."},{"key":"1038_CR66","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40263-016-0340-9","volume":"30","author":"D Plantone","year":"2016","unstructured":"Plantone D, De Angelis F, Doshi A, Chataway J. Secondary progressive multiple sclerosis: definition and measurement. CNS Drugs. 2016;30:517\u201326. https:\/\/doi.org\/10.1007\/s40263-016-0340-9.","journal-title":"CNS Drugs"},{"key":"1038_CR67","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jneuroim.2012.04.019","volume":"249","author":"G Frisullo","year":"2012","unstructured":"Frisullo G, Plantone D, Marti A, Iorio R, Damato V, Nociti V, et al. Type 1 immune response in progressive multiple sclerosis. J Neuroimmunol. 2012;249:112\u20136. https:\/\/doi.org\/10.1016\/j.jneuroim.2012.04.019.","journal-title":"J Neuroimmunol."},{"key":"1038_CR68","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321:175\u201387. https:\/\/doi.org\/10.1001\/jama.2018.20588.","journal-title":"JAMA"},{"key":"1038_CR69","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1606468.","journal-title":"N Engl J Med."},{"key":"1038_CR70","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40263-018-0568-7","volume":"32","author":"YY Syed","year":"2018","unstructured":"Syed YY. Ocrelizumab: a review in multiple sclerosis. CNS Drugs. 2018;32:883\u201390. https:\/\/doi.org\/10.1007\/s40263-018-0568-7.","journal-title":"CNS Drugs"},{"key":"1038_CR71","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11940-018-0496-3","volume":"20","author":"JR Ciotti","year":"2018","unstructured":"Ciotti JR, Cross AH. Disease-modifying treatment in progressive multiple sclerosis. Curr Treat Options Neurol. 2018;20:12. https:\/\/doi.org\/10.1007\/s11940-018-0496-3.","journal-title":"Curr Treat Options Neurol."},{"key":"1038_CR72","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30475-6.","journal-title":"Lancet"},{"key":"1038_CR73","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11910-009-0060-3","volume":"9","author":"KG Su","year":"2009","unstructured":"Su KG, Banker G, Bourdette D, Forte M. Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis. Curr Neurol Neurosci Rep. 2009;9:411\u20137. https:\/\/doi.org\/10.1007\/s11910-009-0060-3.","journal-title":"Curr Neurol Neurosci Rep."},{"key":"1038_CR74","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/biology8020037","volume":"8","author":"IP de Barcelos","year":"2019","unstructured":"de Barcelos IP, Troxell RM, Graves JS. Mitochondrial dysfunction and multiple sclerosis. Biology (Basel). 2019;8:37. https:\/\/doi.org\/10.3390\/biology8020037.","journal-title":"Biology (Basel)."},{"key":"1038_CR75","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/bs.ircmb.2016.08.003","volume":"328","author":"S Patergnani","year":"2017","unstructured":"Patergnani S, Fossati V, Bonora M, Giorgi C, Marchi S, Missiroli S, et al. Mitochondria in multiple sclerosis: molecular mechanisms of pathogenesis. Int Rev Cell Mol Biol. 2017;328:49\u2013103. https:\/\/doi.org\/10.1016\/bs.ircmb.2016.08.003.","journal-title":"Int Rev Cell Mol Biol."},{"key":"1038_CR76","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.mito.2009.12.141","volume":"10","author":"R Schoenfeld","year":"2010","unstructured":"Schoenfeld R, Wong A, Silva J, Li M, Itoh A, Horiuchi M, et al. Oligodendroglial differentiation induces mitochondrial genes and inhibition of mitochondrial function represses oligodendroglial differentiation. Mitochondrion. 2010;10:143\u201350. https:\/\/doi.org\/10.1016\/j.mito.2009.12.141.","journal-title":"Mitochondrion"},{"key":"1038_CR77","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/ana.20736","volume":"59","author":"R Dutta","year":"2006","unstructured":"Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006;59:478\u201389. https:\/\/doi.org\/10.1002\/ana.20736.","journal-title":"Ann. Neurol."},{"key":"1038_CR78","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ana.22109","volume":"69","author":"GR Campbell","year":"2011","unstructured":"Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol. 2011;69:481\u201392. https:\/\/doi.org\/10.1002\/ana.22109.","journal-title":"Ann Neurol."},{"issue":"8","key":"1038_CR79","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1177\/1352458517711568","volume":"24","author":"IY Choi","year":"2018","unstructured":"Choi IY, Lee P, Adany P, Hughes AJ, Belliston S, Denney DR, et al. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis. Mult Scler J. 2018;24(8):1029\u201338. https:\/\/doi.org\/10.1177\/1352458517711568.","journal-title":"Mult Scler J."},{"key":"1038_CR80","doi-asserted-by":"publisher","first-page":"8168","DOI":"10.1073\/pnas.0402765101","volume":"101","author":"MJ Craner","year":"2004","unstructured":"Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Waxman SG. Molecular changes in neurons in multiple sclerosis: Altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+\/Ca2+ exchanger. Proc Natl Acad Sci U S A. 2004;101:8168\u201381673. https:\/\/doi.org\/10.1073\/pnas.0402765101.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"1038_CR81","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1523\/JNEUROSCI.12-02-00430.1992","volume":"12","author":"PK Stys","year":"1992","unstructured":"Stys PK, Waxman SG, Ransom BR. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger. J Neurosci. 1992;12:430\u20139. https:\/\/doi.org\/10.1523\/JNEUROSCI.12-02-00430.1992.","journal-title":"J Neurosci."},{"key":"1038_CR82","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/ije\/27.5.845","volume":"27","author":"P Ghadirian","year":"1998","unstructured":"Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Int J Epidemiol. 1998;27:845\u201352. https:\/\/doi.org\/10.1093\/ije\/27.5.845.","journal-title":"Int J Epidemiol."},{"key":"1038_CR83","first-page":"44","volume":"111","author":"GN Bisaga","year":"2011","unstructured":"Bisaga GN, Odinak MM, Boiko AN, Mel\u2019nik YB, Popova NF. Possibilities of treatment of multiple sclerosis exacerbations without corticosteroids: a role of metabolic and antioxidant therapy. Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111:44\u201384.","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova."},{"key":"1038_CR84","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444\u201352. https:\/\/doi.org\/10.1212\/wnl.33.11.1444.","journal-title":"Neurology"},{"key":"1038_CR85","first-page":"439","volume":"19","author":"M Naghashpour","year":"2016","unstructured":"Naghashpour M, Amani R, Sarkaki A, Ghadiri A, Samarbafzadeh A, Jafarirad S, et al. Brain-derived neurotrophic and immunologic factors: Beneficial effects of riboflavin on motor disability in murine model of multiple sclerosis. Iran J Basic Med Sci. 2016;19:439\u201348.","journal-title":"Iran J Basic Med Sci."},{"key":"1038_CR86","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(98)11058-9","volume":"354","author":"GJ Hankey","year":"1999","unstructured":"Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999;354:407\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(98)11058-9.","journal-title":"Lancet"},{"key":"1038_CR87","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/978-3-7091-9334-1_84","volume":"60","author":"AL Betz","year":"1994","unstructured":"Betz AL, Ren XD, Ennis SR, Hultquist DE. Riboflavin reduces edema in focal cerebral ischemia. Acta Neurochir Suppl (Wien). 1994;60:314\u20137. https:\/\/doi.org\/10.1007\/978-3-7091-9334-1_84.","journal-title":"Acta Neurochir Suppl (Wien)."},{"key":"1038_CR88","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1006\/bbrc.1995.1932","volume":"212","author":"CP Mack","year":"1995","unstructured":"Mack CP, Hultquist DE, Shlafer M. Myocardial flavin reductase and riboflavin: a potential role in decreasing reoxygenation injury. Biochem Biophys Res Commun. 1995;212:35\u201340. https:\/\/doi.org\/10.1006\/bbrc.1995.1932.","journal-title":"Biochem Biophys Res Commun."},{"key":"1038_CR89","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1089\/neu.2005.22.1112","volume":"22","author":"MR Hoane","year":"2005","unstructured":"Hoane MR, Wolyniak JG, Akstulewicz SL. Administration of riboflavin improves behavioral outcome and reduces edema formation and glial fibrillary acidic protein expression after traumatic brain injury. J Neurotrauma. 2005;22:1112\u201322. https:\/\/doi.org\/10.1089\/neu.2005.22.1112.","journal-title":"J Neurotrauma."},{"key":"1038_CR90","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/ng0595-111","volume":"10","author":"P Frosst","year":"1995","unstructured":"Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111\u20133. https:\/\/doi.org\/10.1038\/ng0595-111.","journal-title":"Nat. Genet."},{"key":"1038_CR91","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1136\/jmg.40.8.619","volume":"40","author":"B Wilcken","year":"2003","unstructured":"Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Redlund M, et al. Geographical and ethnic variation of the 677C>T allele of 5, 10 methylenetetrahydrofolate reductase (MTHFR): Findings from over 7000 newborns from 16 areas world wide. J Med Genet. 2003;40:619\u201325. https:\/\/doi.org\/10.1136\/jmg.40.8.619.","journal-title":"J Med Genet."},{"key":"1038_CR92","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1161\/CIRCULATIONAHA.106.613299","volume":"114","author":"H McNulty","year":"2006","unstructured":"McNulty H, Dowey LRC, Strain JJ, Dunne A, Ward M, Molloy AM, et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C\u2192T polymorphism. Circulation. 2006;114:e65. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.613299 (author reply e66).","journal-title":"Circulation"},{"key":"1038_CR93","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/sj.ejhg.5201914","volume":"15","author":"X Qian","year":"2007","unstructured":"Qian X, Lu Z, Tan M, Liu H, Lu D. A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur J Hum Genet. 2007;15:1239\u201345. https:\/\/doi.org\/10.1038\/sj.ejhg.5201914.","journal-title":"Eur J Hum Genet."},{"key":"1038_CR94","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mam.2016.10.002","volume":"53","author":"H McNulty","year":"2017","unstructured":"McNulty H, Strain JJ, Hughes CF, Ward M. Riboflavin, MTHFR genotype and blood pressure: a personalized approach to prevention and treatment of hypertension. Mol Aspects Med. 2017;53:2\u20139. https:\/\/doi.org\/10.1016\/j.mam.2016.10.002.","journal-title":"Mol Aspects Med."},{"key":"1038_CR95","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S0140-6736(11)60872-6","volume":"378","author":"MV Holmes","year":"2011","unstructured":"Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: A meta-analysis of genetic studies and randomised trials. Lancet. 2011;378:584\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(11)60872-6.","journal-title":"Lancet"},{"key":"1038_CR96","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/sj.ejcn.1602666","volume":"61","author":"S Gariballa","year":"2007","unstructured":"Gariballa S, Ullegaddi R. Riboflavin status in acute ischaemic stroke. Eur J Clin Nutr. 2007;61:1237\u201340. https:\/\/doi.org\/10.1038\/sj.ejcn.1602666.","journal-title":"Eur J Clin Nutr."},{"key":"1038_CR97","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ana.25286","volume":"84","author":"A da Silva-Candal","year":"2018","unstructured":"da Silva-Candal A, P\u00e9rez-D\u00edaz A, Santamar\u00eda M, Correa-Paz C, Rodr\u00edguez-Y\u00e1\u00f1ez M, Ard\u00e1 A, et al. Clinical validation of blood\/brain glutamate grabbing in acute ischemic stroke. Ann Neurol. 2018;84:260\u201373. https:\/\/doi.org\/10.1002\/ana.25286.","journal-title":"Ann Neurol."},{"key":"1038_CR98","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.1212\/NXG.0000000000000215","volume":"4","author":"S Camargos","year":"2018","unstructured":"Camargos S, Guerreiro R, Bras J, Mageste LS. Late-onset and acute presentation of Brown\u2013Vialetto\u2013Van Laere syndrome in a Brazilian family. Neurol Genet. 2018;4:e215. https:\/\/doi.org\/10.1212\/NXG.0000000000000215.","journal-title":"Neurol Genet."},{"key":"1038_CR99","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1093\/brain\/awx231","volume":"140","author":"A Manole","year":"2017","unstructured":"Manole A, Jaunmuktane Z, Hargreaves I, Ludtmann MHR, Salpietro V, Bello OD, et al. Clinical, pathological and functional characterization of riboflavin-responsive neuropathy. Brain. 2017;140:2820\u201337. https:\/\/doi.org\/10.1093\/brain\/awx231.","journal-title":"Brain"},{"key":"1038_CR100","unstructured":"Manole A, Houlden H. Riboflavin transporter deficiency neuronopathy. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews\u00ae [Internet].. Seattle (WA): University of Washington, Seattle; 1993-2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK299312\/. Accessed 19 Sep 2020."},{"key":"1038_CR101","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ajhg.2010.02.006","volume":"86","author":"P Green","year":"2010","unstructured":"Green P, Wiseman M, Crow YJ, Houlden H, Riphagen S, Lin JP, et al. Brown\u2013Vialetto\u2013Van Laere syndrome, a Ponto-Bulbar palsy with deafness, is caused by mutations in C20orf54. Am J Hum Genet. 2010;86:485\u20139. https:\/\/doi.org\/10.1016\/j.ajhg.2010.02.006.","journal-title":"Am J Hum Genet."},{"key":"1038_CR102","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10545-010-9242-z","volume":"34","author":"AM Bosch","year":"2011","unstructured":"Bosch AM, Abeling NGGM, Ijlst L, Knoester H, Van Der Pol WL, Stroomer AEM, et al. Brown\u2013Vialetto\u2013Van Laere and Fazio Londe syndrome is associated with a riboflavin transporter defect mimicking mild MADD: A new inborn error of metabolism with potential treatment. J Inherit Metab Dis. 2011;34:159\u201364. https:\/\/doi.org\/10.1007\/s10545-010-9242-z.","journal-title":"J Inherit Metab Dis."},{"key":"1038_CR103","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1750-1172-7-83","volume":"7","author":"AM Bosch","year":"2012","unstructured":"Bosch AM, Stroek K, Abeling NG, Waterham HR, Ijlst L, Wanders RJA. The Brown\u2013Vialetto\u2013Van Laere and Fazio Londe syndrome revisited: Natural history, genetics, treatment and future perspectives. Orphanet J Rare Dis. 2012;7:83. https:\/\/doi.org\/10.1186\/1750-1172-7-83.","journal-title":"Orphanet J Rare Dis."},{"key":"1038_CR104","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/brain\/awt315","volume":"137","author":"AR Foley","year":"2014","unstructured":"Foley AR, Menezes MP, Pandraud A, Gonzalez MA, Al-Odaib A, Abrams AJ, et al. Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain. 2014;137:44\u201356. https:\/\/doi.org\/10.1093\/brain\/awt315.","journal-title":"Brain"},{"key":"1038_CR105","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1750-1172-3-9","volume":"3","author":"S Sathasivam","year":"2008","unstructured":"Sathasivam S. Brown\u2013Vialetto\u2013Van Laere syndrome. Orphanet J Rare Dis. 2008;3:9. https:\/\/doi.org\/10.1186\/1750-1172-3-9.","journal-title":"Orphanet J Rare Dis."},{"key":"1038_CR106","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/jimd.12053","volume":"42","author":"B O\u2019Callaghan","year":"2019","unstructured":"O\u2019Callaghan B, Bosch AM, Houlden H. An update on the genetics, clinical presentation, and pathomechanisms of human riboflavin transporter deficiency. J Inherit Metab Dis. 2019;42:598\u2013607. https:\/\/doi.org\/10.1002\/jimd.12053.","journal-title":"J Inherit Metab Dis."},{"key":"1038_CR107","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10545-016-9924-2","volume":"39","author":"B Jaeger","year":"2016","unstructured":"Jaeger B, Bosch AM. Clinical presentation and outcome of riboflavin transporter deficiency: mini review after five years of experience. J Inherit Metab Dis. 2016;39:559\u201364. https:\/\/doi.org\/10.1007\/s10545-016-9924-2.","journal-title":"J Inherit Metab Dis."},{"key":"1038_CR108","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4103\/JPN.JPN_131_17","volume":"13","author":"M Garg","year":"2018","unstructured":"Garg M, Kulkarni S, Hegde A, Shah K. Riboflavin treatment in genetically proven Brown\u2013Vialetto\u2013Van Laere syndrome. J Pediatr Neurosci. 2018;13:471\u20133. https:\/\/doi.org\/10.4103\/JPN.JPN_131_17.","journal-title":"J Pediatr Neurosci."},{"key":"1038_CR109","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/ng1096-157","volume":"14","author":"JJ Carvajal","year":"1996","unstructured":"Carvajal JJ, Pook MA, dos Santos M, Doudney K, Hillermann R, Minogue S, et al. The Friedreich\u2019s ataxia gene encodes a novel phosphatidylinositol-4-phosphate 5-kinase. Nat Genet. 1996;14:157\u201362. https:\/\/doi.org\/10.1038\/ng1096-157.","journal-title":"Nat Genet."},{"key":"1038_CR110","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.24249","volume":"76","author":"YK Chutake","year":"2014","unstructured":"Chutake YK, Lam C, Costello WN, Anderson M, Bidichandani SI. Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length. Ann Neurol. 2014;76:522\u20138. https:\/\/doi.org\/10.1002\/ana.24249.","journal-title":"Ann Neurol."},{"key":"1038_CR111","first-page":"554","volume":"59","author":"A Filla","year":"1996","unstructured":"Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, Campanella G, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet. 1996;59:554\u201360.","journal-title":"Am J Hum Genet."},{"key":"1038_CR112","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/ana.24595","volume":"79","author":"CA Galea","year":"2016","unstructured":"Galea CA, Huq A, Lockhart PJ, Tai G, Corben LA, Yiu EM, et al. Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia. Ann Neurol. 2016;79:485\u201395. https:\/\/doi.org\/10.1002\/ana.24595.","journal-title":"Ann Neurol."},{"key":"1038_CR113","doi-asserted-by":"publisher","first-page":"e8872","DOI":"10.1371\/journal.pone.0008872","volume":"5","author":"P Gonzalez-Cabo","year":"2010","unstructured":"Gonzalez-Cabo P, Ros S, Palau F. Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency. PLoS ONE. 2010;5:e8872. https:\/\/doi.org\/10.1371\/journal.pone.0008872.","journal-title":"PLoS ONE"},{"key":"1038_CR114","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/ane.12141","volume":"129","author":"J Arpa","year":"2014","unstructured":"Arpa J, Sanz-Gallego I, Rodr\u00edguez-de-Rivera FJ, Dom\u00ednguez-Melc\u00f3n FJ, Prefasi D, Oliva-Navarro J, et al. Triple therapy with deferiprone, idebenone and riboflavin in Friedreich\u2019s ataxia\u2014open-label trial. Acta Neurol Scand. 2014;129:32\u201340.","journal-title":"Acta Neurol Scand."},{"key":"1038_CR115","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12311-013-0482-y","volume":"12","author":"J Arpa","year":"2013","unstructured":"Arpa J, Sanz-Gallego I, Rodr\u00edguez-de-Rivera FJ, Dom\u00ednguez-Melc\u00f3n FJ, Prefasi D, Oliva-Navarro J, et al. Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich\u2019s ataxia: an open-label trial. Cerebellum. 2013;12:713\u201320.","journal-title":"Cerebellum"},{"key":"1038_CR116","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1016\/S0140-6736(18)30727-X","volume":"391","author":"J Rahman","year":"2018","unstructured":"Rahman J, Rahman S. Mitochondrial medicine in the omics era. Lancet. 2018;391:2560\u201374.","journal-title":"Lancet"},{"issue":"Pt B","key":"1038_CR117","doi-asserted-by":"publisher","first-page":"106546","DOI":"10.1016\/j.yebeh.2019.106546","volume":"101","author":"S Rahman","year":"2019","unstructured":"Rahman S. Advances in the treatment of mitochondrial epilepsies. Epilepsy Behav. 2019;101(Pt B):106546. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106546.","journal-title":"Epilepsy Behav."},{"key":"1038_CR118","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev-genom-091416-035426","volume":"18","author":"L Craven","year":"2017","unstructured":"Craven L, Alston CL, Taylor RW, Turnbull DM. Recent advances in mitochondrial disease. Annu Rev Genomics Hum Genet. 2017;18:257\u201375. https:\/\/doi.org\/10.1146\/annurev-genom-091416-035426.","journal-title":"Annu Rev Genomics Hum Genet."},{"key":"1038_CR119","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13023-018-0784-8","volume":"13","author":"BM Repp","year":"2018","unstructured":"Repp BM, Mastantuono E, Alston CL, Schiff M, Haack TB, R\u00f6tig A, et al. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective? Orphanet J Rare Dis. 2018;13:120. https:\/\/doi.org\/10.1186\/s13023-018-0784-8.","journal-title":"Orphanet J Rare Dis."},{"key":"1038_CR120","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.bbabio.2016.03.031","volume":"1857","author":"L S\u00e1nchez-Caballero","year":"2016","unstructured":"S\u00e1nchez-Caballero L, Guerrero-Castillo S, Nijtmans L. Unraveling the complexity of mitochondrial complex I assembly: a dynamic process. Biochim Biophys Acta. 2016;1857:980\u201390. https:\/\/doi.org\/10.1016\/j.bbabio.2016.03.031.","journal-title":"Biochim Biophys Acta."},{"key":"1038_CR121","doi-asserted-by":"publisher","first-page":"32309","DOI":"10.1074\/jbc.M504460200","volume":"280","author":"R Ensenauer","year":"2005","unstructured":"Ensenauer R, He M, Willard J-M, Goetzman ES, Corydon TJ, Vandahl BB, et al. Human acyl-CoA Dehydrogenase-9 plays a novel role in the mitochondrial \u03b2-oxidation of unsaturated fatty acids. J Biol Chem. 2005;280:32309\u201316. https:\/\/doi.org\/10.1074\/jbc.M504460200.","journal-title":"J Biol Chem."},{"key":"1038_CR122","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1093\/hmg\/ddv074","volume":"24","author":"M Schiff","year":"2015","unstructured":"Schiff M, Haberberger B, Xia C, Mohsen A-W, Goetzman ES, Wang Y, et al. Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency. Hum Mol Genet. 2015;24:3238\u201347. https:\/\/doi.org\/10.1093\/hmg\/ddv074.","journal-title":"Hum Mol Genet."},{"key":"1038_CR123","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/s0006-291x(02)02336-7","volume":"297","author":"J Zhang","year":"2002","unstructured":"Zhang J, Zhang W, Zou D, Chen G, Wan T, Zhang M, et al. Cloning and functional characterization of ACAD-9, a novel member of human acyl-CoA dehydrogenase family. Biochem Biophys Res Commun. 2002;297:1033\u201342. https:\/\/doi.org\/10.1016\/s0006-291x(02)02336-7.","journal-title":"Biochem Biophys Res Commun."},{"key":"1038_CR124","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.bbadis.2011.09.009","volume":"1812","author":"TG Lucas","year":"2011","unstructured":"Lucas TG, Henriques BJ, Rodrigues JV, Bross P, Gregersen N, Gomes CM. Cofactors and metabolites as potential stabilizers of mitochondrial acyl-CoA dehydrogenases. Biochim Biophys Acta. 2011;1812:1658\u201363. https:\/\/doi.org\/10.1016\/j.bbadis.2011.09.009.","journal-title":"Biochim Biophys Acta."},{"key":"1038_CR125","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejpn.2017.09.004","volume":"22","author":"G Heimer","year":"2018","unstructured":"Heimer G, Eyal E, Zhu X, Ruzzo EK, Marek-Yagel D, Sagiv D, et al. Mutations in AIFM1 cause an X-linked childhood cerebellar ataxia partially responsive to riboflavin. Eur J Paediatr Neurol. 2018;22:93\u2013101. https:\/\/doi.org\/10.1016\/j.ejpn.2017.09.004.","journal-title":"Eur J Paediatr Neurol."},{"key":"1038_CR126","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/17135","volume":"397","author":"SA Susin","year":"1999","unstructured":"Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397:441\u20136. https:\/\/doi.org\/10.1038\/17135.","journal-title":"Nature"},{"key":"1038_CR127","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/sj.cdd.4400527","volume":"6","author":"HK Lorenzo","year":"1999","unstructured":"Lorenzo HK, Susin SA, Penninger J, Kroemer G. Apoptosis inducing factor (AIF): a phylogenetically old, caspase- independent effector of cell death. Cell Death Differ. 1999;6:516\u201324. https:\/\/doi.org\/10.1038\/sj.cdd.4400527.","journal-title":"Cell Death Differ."},{"key":"1038_CR128","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nature01034","volume":"419","author":"JA Klein","year":"2002","unstructured":"Klein JA, Longo-Guess CM, Rossmann MP, Seburn KL, Hurd RE, Frankel WN, et al. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature. 2002;419:367\u201374. https:\/\/doi.org\/10.1038\/nature01034.","journal-title":"Nature"},{"key":"1038_CR129","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.bbrc.2018.02.203","volume":"498","author":"D Liu","year":"2018","unstructured":"Liu D, Liu M, Wang W, Pang L, Wang Z, Yuan C, et al. Overexpression of apoptosis-inducing factor mitochondrion-associated 1 (AIFM1) induces apoptosis by promoting the transcription of caspase3 and DRAM in hepatoma cells. Biochem Biophys Res Commun. 2018;498:453\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2018.02.203.","journal-title":"Biochem Biophys Res Commun."},{"key":"1038_CR130","doi-asserted-by":"publisher","first-page":"e1814","DOI":"10.1038\/cddis.2015.170","volume":"6","author":"K Meyer","year":"2015","unstructured":"Meyer K, Buettner S, Ghezzi D, Zeviani M, Bano D, Nicotera P. Loss of apoptosis-inducing factor critically affects MIA40 function. Cell Death Dis. 2015;6:e1814. https:\/\/doi.org\/10.1038\/cddis.2015.170.","journal-title":"Cell Death Dis"},{"key":"1038_CR131","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ajhg.2010.03.002","volume":"86","author":"D Ghezzi","year":"2010","unstructured":"Ghezzi D, Sevrioukova I, Invernizzi F, Lamperti C, Mora M, D\u2019Adamo P, et al. Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosis-inducing factor. Am J Hum Genet. 2010;86:639\u201349. https:\/\/doi.org\/10.1016\/j.ajhg.2010.03.002.","journal-title":"Am J Hum Genet."},{"key":"1038_CR132","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ymgme.2011.09.020","volume":"104","author":"I Berger","year":"2011","unstructured":"Berger I, Ben-Neriah Z, Dor-Wolman T, Shaag A, Saada A, Zenvirt S, et al. Early prenatal ventriculomegaly due to an AIFM1 mutation identified by linkage analysis and whole exome sequencing. Mol Genet Metabol. 2011;104:517\u201320. https:\/\/doi.org\/10.1016\/j.ymgme.2011.09.020.","journal-title":"Mol Genet Metabol."},{"key":"1038_CR133","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12967-016-0930-9","volume":"14","author":"E Pronicka","year":"2016","unstructured":"Pronicka E, Piekutowska-Abramczuk D, Ciara E, Trubicka J, Rokicki D, Karkuci\u0144ska-Wi\u0119ckowska A, et al. New perspective in diagnostics of mitochondrial disorders: two years\u2019 experience with whole-exome sequencing at a national paediatric centre. J Transl Med. 2016;14:174. https:\/\/doi.org\/10.1186\/s12967-016-0930-9.","journal-title":"J Transl Med."},{"key":"1038_CR134","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/jmedgenet-2014-102961","volume":"52","author":"L Zong","year":"2015","unstructured":"Zong L, Guan J, Ealy M, Zhang Q, Wang D, Wang H, et al. Mutations in apoptosis-inducing factor cause X-linked recessive auditory neuropathy spectrum disorder. J Med Genet. 2015;52:523\u201331. https:\/\/doi.org\/10.1136\/jmedgenet-2014-102961.","journal-title":"J Med Genet."},{"key":"1038_CR135","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ajhg.2012.10.008","volume":"91","author":"C Rinaldi","year":"2012","unstructured":"Rinaldi C, Grunseich C, Sevrioukova IF, Schindler A, Horkayne-Szakaly I, Lamperti C, et al. Cowchock syndrome is associated with a mutation in apoptosis-inducing factor. Am J Hum Genet. 2012;91:1095\u2013102. https:\/\/doi.org\/10.1016\/j.ajhg.2012.10.008.","journal-title":"Am J Hum Genet."},{"key":"1038_CR136","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1212\/WNL.0000000000001613","volume":"84","author":"A Ardissone","year":"2015","unstructured":"Ardissone A, Piscosquito G, Legati A, Langella T, Lamantea E, Garavaglia B, et al. A slowly progressive mitochondrial encephalomyopathy widens the spectrum of AIFM1 disorders. Neurology. 2015;84:2193\u20135. https:\/\/doi.org\/10.1212\/WNL.0000000000001613.","journal-title":"Neurology"},{"key":"1038_CR137","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.mito.2015.01.001","volume":"21","author":"M Kettwig","year":"2015","unstructured":"Kettwig M, Schubach M, Zimmermann FA, Klinge L, Mayr JA, Biskup S, et al. From ventriculomegaly to severe muscular atrophy: expansion of the clinical spectrum related to mutations in AIFM1. Mitochondrion. 2015;21:12\u20138. https:\/\/doi.org\/10.1016\/j.mito.2015.01.001.","journal-title":"Mitochondrion"},{"key":"1038_CR138","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/ejhg.2015.141","volume":"24","author":"D Diodato","year":"2016","unstructured":"Diodato D, Tasca G, Verrigni D, D\u2019Amico A, Rizza T, Tozzi G, et al. A novel AIFM1 mutation expands the phenotype to an infantile motor neuron disease. Eur J Hum Genet. 2016;24:463\u20136. https:\/\/doi.org\/10.1038\/ejhg.2015.141.","journal-title":"Eur J Hum Genet."},{"key":"1038_CR139","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/cge.12792","volume":"91","author":"H Mierzewska","year":"2017","unstructured":"Mierzewska H, Rydzanicz M, Biega\u0144ski T, Kosinska J, Mierzewska-Schmidt M, \u0141ugowska A, et al. Spondyloepimetaphyseal dysplasia with neurodegeneration associated with AIFM1 mutation - a novel phenotype of the mitochondrial disease. Clin Genet. 2017;91:30\u20137. https:\/\/doi.org\/10.1111\/cge.12792.","journal-title":"Clin Genet."},{"key":"1038_CR140","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/jimd.12058","volume":"42","author":"S Balasubramaniam","year":"2019","unstructured":"Balasubramaniam S, Christodoulou J, Rahman S. Disorders of riboflavin metabolism. J Inherit Metab Dis. 2019;42:608\u201319. https:\/\/doi.org\/10.1002\/jimd.12058.","journal-title":"J Inherit Metab Dis."},{"key":"1038_CR141","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ygeno.2013.04.013","volume":"102","author":"DL Dinwiddie","year":"2013","unstructured":"Dinwiddie DL, Smith LD, Miller NA, Atherton AM, Farrow EG, Strenk ME, et al. Diagnosis of mitochondrial disorders by concomitant next-generation sequencing of the exome and mitochondrial genome. Genomics. 2013;102:148\u201356. https:\/\/doi.org\/10.1016\/j.ygeno.2013.04.013.","journal-title":"Genomics"},{"key":"1038_CR142","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10048-013-0355-z","volume":"14","author":"D Lal","year":"2013","unstructured":"Lal D, Becker K, Motameny S, Altm\u00fcller J, Thiele H, N\u00fcrnberg P, et al. Homozygous missense mutation of NDUFV1 as the cause of infantile bilateral striatal necrosis. Neurogenetics. 2013;14:85\u20137. https:\/\/doi.org\/10.1007\/s10048-013-0355-z.","journal-title":"Neurogenetics"},{"key":"1038_CR143","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pediatrneurol.2006.08.007","volume":"36","author":"V Laugel","year":"2007","unstructured":"Laugel V, This-Bernd V, Cormier-Daire V, Speeg-Schatz C, de Saint-Martin A, Fischbach M. Early-onset ophthalmoplegia in Leigh-like syndrome due to NDUFV1 mutations. Pediatr Neurol. 2007;36:54\u20137. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2006.08.007.","journal-title":"Pediatr Neurol."},{"key":"1038_CR144","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.gene.2012.12.024","volume":"516","author":"SE Marin","year":"2013","unstructured":"Marin SE, Mesterman R, Robinson B, Rodenburg RJ, Smeitink J, Tarnopolsky MA. Leigh syndrome associated with mitochondrial complex I deficiency due to novel mutations In NDUFV1 and NDUFS2. Gene. 2013;516:162\u20137. https:\/\/doi.org\/10.1016\/j.gene.2012.12.024.","journal-title":"Gene"},{"key":"1038_CR145","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ejpn.2015.05.002","volume":"19","author":"JM Cameron","year":"2015","unstructured":"Cameron JM, MacKay N, Feigenbaum A, Tarnopolsky M, Blaser S, Robinson BH, et al. Exome sequencing identifies complex I NDUFV2 mutations as a novel cause of Leigh syndrome. Eur J Paediatr Neurol. 2015;19:525\u201332. https:\/\/doi.org\/10.1016\/j.ejpn.2015.05.002.","journal-title":"Eur J Paediatr Neurol."},{"issue":"9","key":"1038_CR146","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-014-0117-5","volume":"22","author":"SC Gr\u00fcnert","year":"2014","unstructured":"Gr\u00fcnert SC. Clinical and genetical heterogeneity of late-onset multiple acyl-coenzyme A dehydrogenase deficiency. Orphanet J Rare Dis. 2014;22(9):117. https:\/\/doi.org\/10.1186\/s13023-014-0117-5.","journal-title":"Orphanet J Rare Dis."},{"key":"1038_CR147","first-page":"2357","volume-title":"The metabolic and molecular bases of inherited disease","author":"FE Frerman","year":"2001","unstructured":"Frerman FE, Goodman SI. Defects of electron transfer flavoprotein and electron transfer flavoprotein-ubiquinone oxidoreductase: glutaric acidemia type II. In: Scriver CR, Sly WS, Childs B, Beaudet AL, Valle D, Kinzler KW, Vogelstein B, editors. The metabolic and molecular bases of inherited disease. New-York: McGraw-Hill; 2001. p. 2357\u201365."},{"key":"1038_CR148","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/00131402-200303000-00005","volume":"4","author":"MC Mareska","year":"2003","unstructured":"Mareska MC, Adams KK, Muenzer J, Frerman F, Braun TG, Howard JF Jr. Adult-onset presentation of glutaric acidemia type II with myopathy. J Clin Neuromuscul Dis. 2003;4:124\u20138. https:\/\/doi.org\/10.1097\/00131402-200303000-00005.","journal-title":"J Clin Neuromuscul Dis."},{"key":"1038_CR149","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.pediatrneurol.2010.05.018","volume":"43","author":"P Wasant","year":"2010","unstructured":"Wasant P, Kuptanon C, Vattanavicharn N, Liammongkolkul S, Ratanarak P, Sangruchi T, et al. Glutaric aciduria type 2, late onset type in Thai siblings with myopathy. Pediatr Neurol. 2010;43:279\u201382. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2010.05.018.","journal-title":"Pediatr Neurol."},{"key":"1038_CR150","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2169\/internalmedicine.50.5172","volume":"50","author":"R Izumi","year":"2011","unstructured":"Izumi R, Suzuki N, Nagata M, Hasegawa T, Abe Y, Saito Y, et al. A case of late onset riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency manifesting as recurrent rhabdomyolysis and acute renal failure. Intern Med. 2011;50:2663\u20138. https:\/\/doi.org\/10.2169\/internalmedicine.50.5172.","journal-title":"Intern Med."},{"key":"1038_CR151","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1056\/NEJM197912273012601","volume":"301","author":"G Dusheiko","year":"1979","unstructured":"Dusheiko G, Kew MC, Joffe BI, Lewin JR, Mantagos S, Tanaka K. Recurrent hypoglycemia associated with glutaric aciduria type II in an adult. N Engl J Med. 1979;301:1405\u20139. https:\/\/doi.org\/10.1056\/NEJM197912273012601.","journal-title":"N Engl J Med."},{"key":"1038_CR152","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1093\/hmg\/dds175","volume":"21","author":"N Cornelius","year":"2012","unstructured":"Cornelius N, Frerman FE, Corydon TJ, Palmfeldt J, Bross P, Gregersen N, et al. Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency. Hum Mol Genet. 2012;21:3435\u201348. https:\/\/doi.org\/10.1093\/hmg\/dds175.","journal-title":"Hum Mol Genet."},{"issue":"Pt 8","key":"1038_CR153","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1093\/brain\/awm054","volume":"130","author":"K Gempel","year":"2007","unstructured":"Gempel K, Topaloglu H, Talim B, Schneiderat P, Schoser BG, Hans VH, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain. 2007;130(Pt 8):2037\u201344. https:\/\/doi.org\/10.1093\/brain\/awm054.","journal-title":"Brain"},{"key":"1038_CR154","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/s0387-7604(97)00573-1","volume":"19","author":"J Tanaka","year":"1997","unstructured":"Tanaka J, Nagai T, Arai H, Inui K, Yamanouchi H, Goto Y, et al. Treatment of mitochondrial encephalomyopathy with a combination of cytochrome C and vitamins B1 and B2. Brain Dev. 1997;19:262\u20137. https:\/\/doi.org\/10.1016\/s0387-7604(97)00573-1.","journal-title":"Brain Dev."},{"key":"1038_CR155","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1590\/s0100-879x2003001000019","volume":"36","author":"CG Coimbra","year":"2003","unstructured":"Coimbra CG, Junqueira VBC. High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson\u2019s disease patients. Braz J Med Biol Res. 2003;36:1409\u201317. https:\/\/doi.org\/10.1590\/s0100-879x2003001000019.","journal-title":"Braz J Med Biol Res."},{"key":"1038_CR156","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.nutres.2012.09.005","volume":"32","author":"LL Xiu","year":"2012","unstructured":"Xiu LL, Lee MS, Wahlqvist ML, Chen RCY, Huang YC, Chen KJ, et al. Low and high homocysteine are associated with mortality independent of B group vitamins but interactive with cognitive status in a free-living elderly cohort. Nutr Res. 2012;32:928\u201339. https:\/\/doi.org\/10.1016\/j.nutres.2012.09.005.","journal-title":"Nutr Res."},{"key":"1038_CR157","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.brainresbull.2006.03.009","volume":"69","author":"AB Barbre","year":"2006","unstructured":"Barbre AB, Hoane MR. Magnesium and riboflavin combination therapy following cortical contusion injury in the rat. Brain Res Bull. 2006;69:639\u201346. https:\/\/doi.org\/10.1016\/j.brainresbull.2006.03.009.","journal-title":"Brain Res Bull."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01038-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01038-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01038-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T14:12:24Z","timestamp":1623420744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01038-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":157,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01038-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"8 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No source of funding was used in the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Domenico Plantone, Matteo Pardini and Giuseppe Rinaldi have no conflict of interest relating to this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data transparency.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"DP: study conception and design, acquisition of data, analysis and interpretation of data, drafting of manuscript and critical revision. MP: acquisition of data and critical revision. GR: acquisition of data and critical revision.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}